Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression
Current Oncology · 2026
DOI: 10.3390/curroncol33050258 ↗Kurz gefasst
Fallbericht in der Zeitschrift Current Oncology, 2026. Verfasst von Lu Ding und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department I of Thoracic Oncology, Peking University Cancer Hosp…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Natural Science Foundation, Beijing Research Ward Excellence Program BRWEP2024W032150100, WU JIEPING MEDICAL FOUNDATION.
Abstract (Originalsprache)
Anaplastic lymphoma kinase (ALK) rearrangement is a well-established oncogenic driver alteration in non-small cell lung cancer (NSCLC), and ALK tyrosine kinase inhibitors (TKIs), particularly lorlatinib, have significantly improved the prognosis of ALK-positive NSCLC patients. Although high programmed death-ligand 1 (PD-L1) expression (≥50%) is generally associated with favorable responses to immune checkpoint inhibitors (ICIs), PD-L1 has not been shown to reliably predict ICI benefit in ALK-rearranged disease, and optimal management after ALK TKI resistance remains challenging. Herein, we report a case of an elderly patient with ALK-rearrangement and exceptionally high PD-L1 expression (TPS ≥ 95%) NSCLC who experienced disease progression following first-line lorlatinib with genetically confirmed MET amplification. The patient subsequently received an exploratory combination of continued lorlatinib plus envafolimab and achieved partial response (PR) with manageable tolerability after 4 months, highlighting a potential sequential strategy that may warrant further investigation in select ALK-positive NSCLC patients exhibiting both bypass pathway activation and exceptionally high PD-L1 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department I of Thoracic Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
ORCID-Profile: Minglei Zhuo
Förderung
- Beijing Natural Science Foundation
- Beijing Research Ward Excellence Program BRWEP2024W032150100
- WU JIEPING MEDICAL FOUNDATION
- Clinical Research Fund for Distinguished Young Scholars of Peking University Cancer Hospital
- Guangzhou Life oasis public service center Research and exchange program in the field of health
- Beijing Xisike Clinical Oncology Research Foundation
- Beijing Vlove Charity Foundation
Zitieren
APA
Ding, L., Nuersulitan, R., Wang, J., Chen, H., & Zhuo, M. (2026). Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression. Current Oncology. https://doi.org/10.3390/curroncol33050258
Vancouver
Ding L, Nuersulitan R, Wang J, Chen H, Zhuo M. Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression. Current Oncology. 2026. doi:10.3390/curroncol33050258
BibTeX
@article{Ding2026,
author = {Ding, Lu and Nuersulitan, Reyizha and Wang, Jingjing and Chen, Hanxiao and Zhuo, Minglei},
title = {Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33050258}
}
EUVIMED